secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2026-09-24T11:47:35+00:00
Accession:  0001339970-26-000065
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma reaches FDA alignment on Phase 3 protocol for efzofitimod in pulmonary sarcoidosis
--------------------------------------------------------------------------------

- Study to start Q4 2026; global, randomized, double-blind, placebo-controlled, 54-week trial.
- Two parallel cohorts: 5.0 mg/kg efzofitimod vs placebo IV every 3 weeks for 17 doses; up to 372 patients.
- Primary endpoint: change from baseline FVC at week 48; key secondary: KSQ-Lung score change at week 48.
- Design supported by EFZO-FIT subgroup data showing clinically meaningful FVC and patient-reported improvements.
- Company expects to need additional capital via equity/debt, grants, collaborations, or licensing for study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000065/0001339970-26-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000065/atyr-20260924.htm
  HTML page:      https://secwatch.observer/filing/0001339970-26-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer